PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.220
-0.240 (-6.94%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. The company has research and development collaboration with ImmunoGenesis, Inc. to enhance cancer immunotherapy using PLEX technology.
PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid Ltd.
| Country | Israel |
| Founded | 2008 |
| IPO Date | Jun 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dikla Czaczkes Akselbrad |
Contact Details
Address: 18 Hasivim Street Petah Tikva, 4959376 Israel | |
| Phone | 972 7 4719 5700 |
| Website | polypid.com |
Stock Details
| Ticker Symbol | PYPD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001611842 |
| CUSIP Number | M8001Q118 |
| ISIN Number | IL0011326795 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs |
| Dikla Czaczkes Akselbrad | Chief Executive Officer and Director |
| Jonny Missulawin | Chief Financial Officer |
| Ori Warshavsky | Chief Operating Officer - US |
| Maria Rubin | Vice President of Operations |
| Tal Vilnai | General Counsel and Corporate Secretary |
| Rivi Lev-ari | Vice President of Human Resource |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 11, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 424B5 | Filing |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 1, 2024 | 6-K | Report of foreign issuer |